Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022 Mar;10(1):68-74.
doi: 10.1016/j.prnil.2021.02.002. Epub 2021 Mar 9.

Androgen deprivation therapy and risk of cognitive dysfunction in men with prostate cancer: is there a possible link?

Affiliations
Review

Androgen deprivation therapy and risk of cognitive dysfunction in men with prostate cancer: is there a possible link?

Myungsun Shim et al. Prostate Int. 2022 Mar.

Abstract

The expansion of the indication to use androgen deprivation therapy (ADT) to treat patients with advanced or metastatic prostate cancer has dramatically increased over the recent decades, resulting in the progress of patients' survival. However, chronic health implications can become more apparent as the number of long-term cancer survivors is expected to be increased along with the adverse effect of ADT. In particular, interest in investigating ADT, especially luteinizing hormone-releasing hormone (LHRH) agonist association with cognitive dysfunction has been growing. Previous studies in animals and humans suggest that the level of androgen decreases with age and that cognitive decline occurs with decreases in androgen. Correspondingly, some of the extensive studies using common neurocognitive tests have shown that LHRH agonists may affect specific domains of cognitive function (e.g., visuospatial abilities and executive function). However, the results from these studies have not consistently demonstrated the association because of its intrinsic limitations. Large-scale studies based on electronic databases have also failed to show consistent results to make decisive conclusions because of its heterogeneity, complexity of covariates, and possible risk of biases. Thus, this review article summarizes key findings and discusses the results of several studies investigating the ADT association with cognitive dysfunction and risk of dementia from various perspectives.

Keywords: AD, Alzheimer's disease; ADT, androgen deprivation therapy; Adverse effects; Androgen deprivation; Cognitive dysfunction; DHEA, dehydroepiandrosterone; DHEAS, dehydroepiandrosterone sulfate; DHT, dihydrotestosterone; Dementia; HR, hazard ratio; LHRH, luteinizing hormone-releasing hormone; NHIS, National Health Insurance Service; PCa, Prostate cancer; Prostate cancer; SHBG, sex hormone-binding globulin.

PubMed Disclaimer

Conflict of interest statement

Nothing to declare.

Figures

Fig. 1
Fig. 1
The potential mechanism of testosterone affecting cognition.

Similar articles

Cited by

References

    1. McHugh D.J., Root J.C., Nelson C.J., Morris M.J. Androgen-deprivation therapy, dementia, and cognitive dysfunction in men with prostate cancer: how much smoke and how much fire? Cancer. 2018;124:1326–1334. - PMC - PubMed
    1. Liu Y., Uemura H., Ye D., Lee J.Y., Chiong E., Pu Y.S., et al. Prostate cancer in Asia: design of a patient registry to inform real-world treatments, outcomes, and quality of life. Prostate Int. 2019;7:108–113. - PMC - PubMed
    1. Jones C.U., Hunt D., McGowan D.G., Amin M.B., Chetner M.P., Bruner D.W., et al. Radiotherapy and short-term androgen deprivation for localized prostate cancer. N Engl J Med. 2011;365:107–118. - PubMed
    1. Bolla M., Collette L., Blank L., Warde P., Dubois J.B., Mirimanoff R.O., et al. Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study): a phase III randomised trial. Lancet. 2002;360:103–106. - PubMed
    1. Kuykendal A.R., Hendrix L.H., Salloum R.G., Godley P.A., Chen R.C. Guideline-discordant androgen deprivation therapy in localized prostate cancer: patterns of use in the medicare population and cost implications. Ann Oncol. 2013;24:1338–1343. - PMC - PubMed